Stock analysts at Leede Financial issued their FY2027 earnings per share (EPS) estimates for Cipher Pharmaceuticals in a ...

Following the company’s fourth quarter results, Leede Financial analyst Douglas Loe has upgraded Cipher Pharmaceuticals.

Cipher Pharmaceuticals Inc (CPHRF) reports a remarkable 141% increase in net revenue, driven by strategic acquisitions and robust product performance.

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the Cipher Pharmaceuticals quarterly conference call for the company's Full Year and Q4 2024 results. [Operator Instructions].

Research analysts at Leede Financial lowered their FY2025 earnings per share estimates for Cipher Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. Leede Financial ...

Cipher Pharmaceuticals Inc. (CPH) reported its fourth-quarter 2024 earnings, revealing a significant increase in revenue and a notable surge in stock price. Despite missing earnings per share (EPS ...

Cipher Pharmaceuticals Inc. (CPH) reported its fourth-quarter 2024 earnings, revealing a significant increase in revenue and a notable surge in stock price. Despite missing earnings per share (EPS) ...

In a report released today, Justin Keywood from Stifel Nicolaus maintained a Buy rating on Knight Therapeutics (KHTRF – Research Report), with ...

AdventHealth Tampa is the first in the Tampa Bay area to offer a powerful new pump-based treatment option for colorectal ...

Westwater Resources Inc (WWR) is expected to report for 4Q. Williams-Sonoma Inc (WSM) is expected to report $2.90 for 4Q. Yunhong Green CTI Ltd (YHGJ) is expected to report for 4Q.